ATH — Alterity Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$1.96m
- -AU$47.14m
- AU$0.45m
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital
Brief: Alterity Therapeutics Ltd Seeks Trading Halt
Brief: Alterity Therapeutics Posts FY Net Loss After Tax Attributable A$12.1 Million
Brief: Alterity Reports Positive Phase 2 Data for ATH434 in MSA, Shows Clinical Benefit and Biomarker Impact
Brief: Alterity Therapeutics To Provide Corporate Update In Fireside Chat
Brief: Alterity Therapeutics Granted US FDA Fast Track Designation For Lead Candidate To Treat Multiple System Atrophy
Brief: Alterity Therapeutics Announces Granting Of U.S. FDA Fast Track Designation For ATH434
Brief: Alterity Therapeutics Presents Ath434-201 Phase 2 Clinical Trial Results At European Msa Symposium
Brief: Alterity Therapeutics Completes Last Patient Visit In ATH434-202 Open-Label Phase 2 Trial In Multiple System Atrophy
Brief: Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 Million
Australia's Alterity Therapeutics falls on discounted placement
Brief: Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSA
Brief: Alterity Therapeutics Seeks Trading Halt
Brief: Alterity Therapeutics Raises A$2.13 Million Via At-The-Market Facility
Brief: Alterity Therapeutics Seeks Trading Halt
Brief: Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy